Although Fc-engineered mAbs directed against HM1.24 and CD40 showed potent pre-clinical activity, currently no ADCC-optimized antibodies are evaluated in clinical studies for MM therapy [20, 27]. The gene discussed is CD40; the disease is Miyoshi myopathy.